A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples